Active bleeding or pathologic condition that carries a high risk of bleeding (e.g., hereditary hemorrhagic telangiectasia). Patients with bleeding cutaneous lesions not actively requiring transfusions are eligible. Patients who have been uneventfully anti-coagulated with low molecular weight heparin are eligible
Active bleeding or pathologic condition that carries a high risk of bleeding. No bleeding diathesis.
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
History of bleeding disorders which would put a patient at risk for bleeding with anti-coagulation or patients with an increased risk of thromboembolic or hemorrhagic events (e.g., stroke).
Patients with uncontrolled coagulopathies who are at increased risk of bleeding.
Significant risk for bleeding
Subjects with untreated or incompletely treated varices with bleeding or high risk for bleeding; subjects treated with adequate endoscopic therapy (according to institutional standards) without any episodes of recurrent GI bleeding requiring transfusion or hospitalization for at least  months prior to enrollment are eligible
Active bleeding or a pathological condition that is associated with a high risk of bleeding (therapeutic anticoagulation is allowed)
Existing bleeding or condition associated with increased risk of bleeding
Active bleeding or pathologic condition that carries a high risk of bleeding (e.g., hereditary hemorrhagic telangiectasia)
Evidence or history of bleeding diathesis (greater than normal risk of bleeding, i.e., Hereditary Hemorrhagic Telangiectasia type I or HHT-) or coagulopathy in the absence of therapeutic anti-coagulation or any hemorrhage/bleeding event > grade  within  weeks prior to registration; note: patients with full-dose anticoagulants are eligible provided the patient has been on a stable dose for at least  weeks of low molecular weight heparin; therapeutic Coumadin and aspirin doses >  mg daily are not allowed
Patients on full-dose anticoagulation must be on a stable dose (minimum duration  days) of oral anticoagulant or low molecular weight heparin; if receiving warfarin, the patient must have an INR =< . and no active bleeding (that is, no bleeding within  days prior to first dose of protocol therapy) or pathological condition present that carries a high risk of bleeding (for example, tumor involving major vessels or known varices)
Active bleeding or pathologic condition that carries a high risk of bleeding (e.g. hereditary hemorrhagic telangiectasia); patients who have been uneventfully anti-coagulated with low molecular weight heparin are eligible
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as a known bleeding disorder, coagulopathy, or tumor involving major vessels
active bleeding or a high risk of bleeding contraindicating anticoagulant treatment;
Known, increased risk of bleeding
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving (in contact with, invading or encasing) major vessels
Active bleeding or a pathological condition that is associated with a high risk of bleeding (therapeutic anticoagulation is allowed)
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
This criterion applies only to the patients enrolled before August ,  and those enrolled after this date electing to receive bevacizumab; patients with active bleeding or pathologic conditions that carry high risk of bleeding such as a known bleeding disorder, coagulopathy, or tumor involving major vessels
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
Subjects with untreated or incompletely treated varices with bleeding or high risk for bleeding.
Active bleeding or pathologic condition that carries a high risk of bleeding (e.g. hereditary hemorrhagic telangiectasia). Patients who have been uneventfully anti-coagulated with low molecular weight heparin are eligible.
Patients must not have active bleeding or a pathological condition that is associated with a high risk of bleeding
Patients with active bleeding or pathologic conditions that carry high risk of bleeding
Active bleeding or pathologic condition that carries a high risk of bleeding (e.g. hereditary hemorrhagic telangiectasia).
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder or coagulopathy.
Patients must have no evidence of bleeding diathesis or coagulopathy; patients must have no pathologic condition other than mesothelioma that carries a high risk of bleeding
Contraindications to prophylactic dose low molecular weight heparin (LMWH), including \r\n* Patients with recent gastrointestinal bleeding \r\n* History of heparin induce thrombocytopenia on LMWH\r\n* Subjects with previous severe hemorrhagic events on LMWH\r\n* Recent central nervous system bleed, intracranial or spinal lesion at high risk for bleeding\r\n* Active bleeding (major): more than  units transfused in  hours\r\n* Spinal anesthesia/lumbar puncture\r\n* Chronic, clinically significant measurable bleeding >  hours\r\n* Severe platelet dysfunction (uremia, medications, dysplastic hematopoiesis)\r\n* Recent major operation at high risk for bleeding\r\n* Underlying hemorrhagic coagulopathy\r\n* High risk for falls (head trauma)
Patients on full-dose anticoagulants (e.g., warfarin or low molecular weight [LMW] heparin) must meet the following criteria:\r\n* No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
Active bleeding disorders and high likelihood of bleeding or conditions or medications known to increase the risk of bleeding; patients with bleeding diathesis and subjects who are receiving anticoagulation treatment with INR >  are excluded
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
Patients with untreated or incompletely treated varices with bleeding or high-risk for bleeding
Active bleeding or a pathological condition that is associated with a high risk of bleeding
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy (in the absence of therapeutic anticoagulation), or tumor involving major vessels.
Subjects with current/a history of bleeding disorder or coagulopathy or who are at particularly high risk for bleeding complications.
Ongoing risk of bleeding.
International normalized ratio > . on anticoagulant therapy, active bleeding on low molecular weight heparin, or chronic condition with a high risk of bleeding.
Active bleeding or high risk for bleeding contraindicating treatment with LMWH or edoxaban;
Active bleeding; pathological condition that carries a high risk of bleeding; risk of pseudoaneurysm of the internal carotid artery and carotid blowout syndrome.
Patients with an underlying diagnosis or disease state associated with an increased risk of bleeding.
Active bleeding or high risk of bleeding
Evidence or history of bleeding diathesis (greater than normal risk of bleeding, i.e., hereditary hemorrhagic telangiectasia type I or HHT-) or coagulopathy in the absence of therapeutic anti-coagulation or any hemorrhage/bleeding event > grade  within  weeks prior to registration; note: patients with full-dose anticoagulants are eligible provided the patient has been on a stable dose for at least  weeks of low molecular weight heparin; therapeutic Coumadin and aspirin doses >  mg daily are not allowed
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels by imaging, regardless of whether any chance of requiring vascular reconstruction
Evidence of active bleeding or pathologic conditions that carry high risk of bleeding such as known bleeding disorders, coagulopathy or tumor involving major vessels
No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices) within  days prior to registration
Active bleeding or high risk of bleeding in the opinion of the investigator
Participants with untreated or incompletely treated varices with bleeding or high-risk for bleeding
Active bleeding or high risk for bleeding (e.g. known acute gastrointestinal ulcer)
Patients on anticoagulation or with bleeding disorders should be evaluated by a physician for risk/benefit of bleeding disorders with intramuscular injections prior to study enrollment; patients determined to be at high risk for bleeding with intramuscular injections will be excluded
Active bleeding or otherwise considered high risk for hemorrhage (e.g. known acute gastrointestinal ulcer)
Bleeding diathesis, hemorrhagic lesions, active bleeding, and other conditions with a high risk for bleeding
active bleeding or at high risk of bleeding
Any condition resulting in increased risk of bleeding at biopsy.
Active bleeding or high risk of bleeding
Active bleeding or pathologic condition that carries a high risk of bleeding